Calibrant, Yale to Collaborate on Ovarian, Breast Cancer Drug ID Study

Feb 07, 2008

NEW YORK (GenomeWeb News) – Calibrant Biosystems today said that it will collaborate with researchers at the Yale University School of Medicine to identify ovarian and breast cancer drug targets from clinical tissue specimens using Calibrant’s Gemini proteomics platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

A Winning Diagnostic

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

Science in Africa Unevenly Funded

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

Not Enough Progress?

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

This Week in Science

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Main menu